Didier Meulendijks
- Oncology top 5%
- Colorectal Cancer Treatments and Studies 26
- Pancreatic and Hepatic Oncology Research 9
- Cancer Treatment and Pharmacology 8
- Pharmacology top 5%
- Pharmacogenetics and Drug Metabolism 3
-
- Gastric Cancer Management and Outcomes 8
- Pathology and Forensic Medicine top 10%
- Genetic factors in colorectal cancer 4
-
- Biochemical and Molecular Research 6
-
- Chronic Lymphocytic Leukemia Research 5
- Co-authors
- Jan H.M. SchellensAnnemieke CatsJos H. BeijnenMaarten J. DeenenHilde RosingLinda M. HenricksPaul H.M. SmitsMarcel Soesan
- Partner nations
- NetherlandsSwitzerlandUnited Kingdom
In The Last Decade
Didier Meulendijks
46 papers receiving 1.3k citations
Peers
Comparison fields: 5 of 83
- Oncology 835
- Pharmacology 113
- Pulmonary and Respiratory Medicine 310
- Cancer Research 126
- Pathology and Forensic Medicine 135
Countries citing papers authored by Didier Meulendijks
This map shows the geographic impact of Didier Meulendijks's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Didier Meulendijks with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Didier Meulendijks more than expected).
Fields of papers citing papers by Didier Meulendijks
This network shows the impact of papers produced by Didier Meulendijks. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Didier Meulendijks. The network helps show where Didier Meulendijks may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Didier Meulendijks, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 5 | |
| 2 | 2025 | 1 | |
| 3 | 2024 | 1 | |
| 4 | 2023 | 2 | |
| 5 | 2023 | 4 | |
| 6 | 2021 | 23 | |
| 7 | 2020 | 3 | |
| 8 | 2020 | 1 | |
| 9 | 2016 | 18 | |
| 10 | 2016 | 34 | |
| 11 | 2016 | 40 | |
| 12 | 2016 | 75 | |
| 13 | 2016 | 23 | |
| 14 | 2015 | 12 | |
| 15 | 2015 | 77 | |
| 16 | 2015 | 47 | |
| 17 | 2015 | 12 | |
| 18 | 2014 | 32 | |
| 19 | 2014 | 54 | |
| 20 | 2010 | 60 |
About Didier Meulendijks
Didier Meulendijks is a scholar working on Oncology, Genetics and Pulmonary and Respiratory Medicine, having authored 47 papers that have together received 1.3k indexed citations. Recurring topics across this work include Colorectal Cancer Treatments and Studies (26 papers), Pancreatic and Hepatic Oncology Research (9 papers), Gastric Cancer Management and Outcomes (8 papers), Cancer Treatment and Pharmacology (8 papers), Biochemical and Molecular Research (6 papers), Chronic Lymphocytic Leukemia Research (5 papers), Genetic factors in colorectal cancer (4 papers) and Pharmacogenetics and Drug Metabolism (3 papers). The work is most often cited by research in Oncology (835 citations), Pharmacology (113 citations) and Pulmonary and Respiratory Medicine (310 citations). Didier Meulendijks has collaborated with scholars based in Netherlands, Switzerland and United Kingdom. Frequent co-authors include Jan H.M. Schellens, Annemieke Cats, Jos H. Beijnen, Maarten J. Deenen, Hilde Rosing, Linda M. Henricks, Paul H.M. Smits, Marcel Soesan, Henk Boot and Caroline M.P.W. Mandigers. Their work appears in journals such as Journal of Clinical Oncology, Cancer and Clinical Cancer Research.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.